Delaware Court of Chancery Reaffirms High Bar for Caremark Oversight Liability: Lessons from the In re The Boeing Co. Derivative Litigation
Executive Summary
On August 13, 2026, the Delaware Court of Chancery issued a landmark ruling in In re The Boeing Co. Derivative Litigation, dismissing Caremark oversight claims against Boeing’s current and former directors and officers with prejudice. The decision, authored by Justice Morgan T. Zurn (recently appointed to the Delaware Supreme Court and sitting by designation in the Court of Chancery), reinforces the exacting bad-faith standard plaintiffs must satisfy to establish oversight liability under Delaware law and provides important reassurance to directors who maintain functioning oversight systems. This 2026 ruling represents the second major Caremark decision arising from Boeing’s 737 MAX program in the Court of Chancery. It follows a 2021 decision and, with the inverse result, reflects how Boeing’s subsequent governance reforms positioned the company to defeat the later claims.
Background
The litigation arose from a January 5, 2024, incident in which a door plug detached from an Alaska Airlines Boeing 737 MAX during flight, forcing an emergency landing. Stockholder plaintiffs brought derivative Caremark claims against Boeing’s directors and officers, alleging two principal failures: (1) failure to respond in good faith to red flags of systemic manufacturing and safety deficiencies; and (2) implementation of production targets that could not be safely or lawfully met.
This case followed Boeing’s earlier 737 MAX crashes in October 2018 (Lion Air Flight JT 610) and March 2019 (Ethiopian Airlines Flight ET 302), which had already resulted in significant corporate governance reforms. Those reforms included the creation of an independent aerospace safety board committee, extensive board and committee reporting requirements, and the formation of a new safety organization. The plaintiffs argued that, despite these reforms, the Board failed to discharge its oversight duties with respect to ongoing manufacturing and safety risks.
In an earlier 2021 decision, the Court of Chancery had denied a motion to dismiss Caremark claims arising from the 2018 and 2019 crashes, finding that plaintiffs had adequately pled that the Board lacked any committee charged with direct responsibility for monitoring airplane safety and had no regular process for receiving safety information. Boeing’s subsequent governance reforms resulted in a different outcome with respect to the later Caremark claims.
Core Legal Issues and the Court’s Reasoning
A. The Caremark Standard: Bad Faith as the Central Limiting Principle
The Court framed its analysis around the threshold question of demand futility under Court of Chancery Rule 23.1, asking whether a majority of the Board faced a substantial likelihood of Caremark liability such that a pre-suit demand on the Board would have been futile.
The Court reiterated that Caremark liability requires more than gross negligence. Plaintiffs must plead particularized facts demonstrating an “intentional dereliction of duty” or “conscious disregard for one’s responsibilities” amounting to a breach of the fiduciary duty of loyalty. As Delaware law presumes that directors perform their duties in good faith and with reasonable care, the bar for Caremark liability remains exceptionally high.
Critically, the Court emphasized that fiduciary duties do not demand omniscience: “Fiduciaries who make a good-faith effort to implement and attend to a reasonable board-level reporting system satisfy their baseline oversight duty, and Delaware law does not demand omniscience.”
B. Reaffirmation of the Business Judgment Rule - Legal Compliance vs. Business Risk Oversight
A central aspect of the decision was the Court’s reinforcement of the distinction between oversight of legal compliance risks and oversight of general business risks. The Court emphasized that:
Legal compliance risks are “black and white”: Directors do not have discretion to violate positive law, and the standards governing their conduct are clear.
Business risk oversight receives broader deference: Directors have more business judgment discretion in managing general business risks, where courts are reluctant to second-guess good-faith business judgments in hindsight.
The Court noted that attaching the same liability standard to operational decisions would require determining in hindsight whether a business judgment was “right” – an “almost impossible” task.
C. “If Everything Is a Red Flag, Then Nothing Is”
The Court characterized the alleged “red flags” raised by plaintiffs, including workforce inexperience and supply chain defects, as general operational concerns speaking to business risks rather than legal risks. The Court found that these purported warnings were, at most, “yellow flags” of operational concerns that demonstrated the reporting system was working, not failing.
The Court rejected plaintiffs’ attempt to recast Boeing’s robust reporting practices as evidence of disloyalty, stating that extensive reporting on safety, manufacturing, and compliance 3 risks, together with management’s responsive actions, should not be “recast from a best practice into evidence of disloyalty.”
D. Production Targets and Good Faith Business Judgment
The Court rejected plaintiffs’ theory that Boeing’s maintenance of production targets despite safety concerns implied bad faith. Instead, the Court found that the record showed Boeing adjusted or delayed production targets in response to informed assessments of changing conditions, which supported the presumption of good faith.
The Court held that, absent particularized allegations that directors knowingly caused the corporation to violate positive law or consciously disregarded clear warnings that the corporation was headed for serious corporate trauma, a later corporate trauma does not support an inference that the board acted in bad faith.`
Key Takeaways and Practical Recommendations
Clients should consider the following actions to mitigate Caremark exposure and ensure compliance with Delaware oversight duties:
1. Establish Robust Board-Level Reporting Systems
Implement formal reporting systems tailored to mission-critical legal and compliance risks.
Ensure that reporting systems include clear escalation channels for red flags.
Document the design and implementation of these systems in board minutes and resolutions.
2. Maintain Detailed Books and Records
Keep contemporaneous records of board and committee meetings, including discussions of safety, manufacturing, and compliance risks.
Document management’s responses to identified risks.
Preserve records of investigations and follow-up actions.
3. Differentiate Legal Compliance from Business Risk Oversight
Establish separate oversight protocols for legal compliance risks (where standards are clear) and business risks (where directors have broader discretion).
Ensure that legal compliance oversight includes clear protocols for monitoring adherence to positive law.
For business risks, document the board’s informed decision-making process.
4. Respond Proactively to Identified Risks
When risks are identified, ensure that management responds promptly and that the board oversees those responses.
Document the board’s oversight of management’s remediation efforts.
Avoid the appearance of ignoring identified risks.
5. Adjust Business Decisions Responsively
When production targets or business decisions must be adjusted in response to changing conditions, document the rationale for those adjustments.
Ensure that adjustments are based on informed assessments, not on a desire to maintain unrealistic targets.
6. Consider Mission-Critical Risk Committees
For companies in industries with mission-critical risks (e.g., aviation, pharmaceuticals, financial services), consider establishing board committees with direct responsibility for monitoring those risks.
Ensure that committee mandates are clear and that committee activities are documented.
7. Prepare for Demand-Futility Scrutiny
Recognize that the demand-futility stage is often where Caremark claims are won or lost.
Ensure that board records demonstrate active oversight and good-faith decision-making.
Consider periodic reviews of board records to ensure they would support a defense against Caremark claims.
8. Leverage Governance Reforms as a Defense
Companies that have implemented governance reforms following prior incidents should ensure those reforms are well-documented and actively maintained.
Governance reforms can serve as powerful evidence of good-faith oversight efforts.
Conclusion
The In re The Boeing Co. decision provides important reassurance to directors of Delaware corporations that the high threshold for Caremark liability remains intact. Boards that maintain functioning oversight systems, regularly monitor for legal compliance, and make informed decisions about business risks will be afforded a strong presumption of good faith.
However, the decision also serves as a reminder that Caremark claims remain a significant litigation risk, particularly for companies in industries with mission-critical safety or compliance obligations. The contrast between the 2021 decision (which allowed Caremark claims to survive based on Boeing's pre-reform oversight failures) and the 2026 decision (which dismissed claims based on Boeing's post-reform oversight systems) demonstrates the tangible value of robust governance practices.
For more information or to discuss how these developments may affect your company, please contact Tammara Fort, Head of M&A, or Samara Thomas, Of Counsel.
